Comparative Pharmacology
Head-to-head clinical analysis: ADVIL CONGESTION RELIEF versus MEFENAMIC ACID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADVIL CONGESTION RELIEF versus MEFENAMIC ACID.
ADVIL CONGESTION RELIEF vs MEFENAMIC ACID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ibuprofen: non-selective COX-1/COX-2 inhibitor reducing prostaglandin synthesis; phenylephrine: alpha-1 adrenergic receptor agonist causing vasoconstriction
Reversible inhibition of cyclooxygenase (COX-1 and COX-2) leading to decreased prostaglandin synthesis; exhibits both central and peripheral analgesic effects.
1 tablet (ibuprofen 200 mg / phenylephrine 10 mg) orally every 4 hours while symptoms persist, not to exceed 6 tablets in 24 hours.
500 mg orally as an initial dose, followed by 250 mg every 6 hours as needed, not to exceed 1 week.
None Documented
None Documented
Ibuprofen: 2-4 hours (short half-life requires frequent dosing). Pseudoephedrine: 5-8 hours (longer in alkaline urine). Context: Half-life prolonged in renal impairment.
Clinical Note
moderateMefenamic acid + Gatifloxacin
"Mefenamic acid may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderateMefenamic acid + Rosoxacin
"Mefenamic acid may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderateMefenamic acid + Levofloxacin
"Mefenamic acid may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderateMefenamic acid + Trovafloxacin
Terminal half-life is 2-4 hours; prolonged in hepatic impairment and overdose.
Renal: ~90% as unchanged drug and metabolites (ibuprofen: <10% unchanged, pseudoephedrine: 43-96% unchanged). Biliary/fecal: minimal (<5%).
Primarily renal (52% as glucuronide metabolites, <6% unchanged) and fecal (20-30% via biliary elimination).
Category C
Category D/X
NSAID/Decongestant Combination
NSAID
"Mefenamic acid may increase the neuroexcitatory activities of Trovafloxacin."